Brolucizumab (RTH258) for the treatment of wet age-related macular degeneration
Brolucizumab for the treatment of wet age-related macular degeneration
Brolucizumab Reports Retinal Fluid Reduction in Phase 3 Analysis
New phase 3 trial data shows that brolucizumab (RTH258) 6 mg results in less instances of detected retinal fluid in treated patients versus those treated with aflibercept. The indication of treatment for the key marker of neovascular age-related macular degeneration (nAMD) lends to the hope that the humanized single-chain antibody fragment (scFv) can reach the market as a first-of-its-kind therapy.
Brolucizumab Reports Retinal Fluid Reduction in Phase 3 Analysis
New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid
Novartis announced a new data analysis showing that retinal fluid was detected less often in patients treated with brolucizumab (RTH258) 6 mg versus aflibercept over four visits between weeks 36 to 48[1]. Retinal fluid is a key marker of disease activity in neovascular age-related macular degeneration (nAMD). The data, from pre-specified secondary endpoints of the Phase III HAWK and HARRIER trials, were presented at EURETINA 2018 as a follow-up to data presented in November 2017.
Phase III clinical trials of brolucizumab in patients with neovascular age-related macular degeneration
What is brolucizumab (also known as RTH258)?
- A unique, small (26 kDa), humanized, investigational single-chain antibody fragment, which is a potent inhibitor of vascular endothelial growth factor (VEGF) 1,2,3
- Abnormally high levels of VEGF are key in the development of neovascular age-related macular degeneration (nAMD), resulting in the formation of abnormal blood vessels in the retina and increased retinal thickness, due to fluid accumulation within or beneath the retinal layers 4
- nAMD is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America, Europe, Australia and Asia, impacting an estimated 20 to 25 million people worldwide 5,6
- The e cacy and safety of brolucizumab in patients with nAMD is being tested in two pivotal Phase III studies called HAWK and HARRIER 7
Übersicht Brolucizumab zur Behandlung der altersbedingten feuchten Makuladegeneration (AMD)
Wikipedia: https://en.wikipedia.org/wiki/Brolucizumab